April Fool’s Day wasn’t mentioned until the parting comment of Tuesday’s Endocrinologic and Metabolic Drugs Advisory Committee’s (EMDAC) meeting to discuss Mannkind Corp.’s Afrezza, when the FDA’s Jean-Marc Guettier thanked everyone at the meeting for showing up on the first of April. But Mannkind officials had to be pinching themselves when the advisory committee (adcom) members came squarely down on the side of the drug for both type 1 and type 2 diabetes.